Thymosin Alpha-1 vs LL-37

Side-by-side comparison of Thymosin Alpha-1, LL-37 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Thymosin Alpha-1 Thymosin Alpha-1 (Tα1) Longevity LL-37 LL-37 (Human Cathelicidin Antimicrobial Peptide) Recovery
Basics
Molecular type Thymic PeptideHuman Cathelicidin
Amino acids 2837
Molecular weight 3,108.4 Da4,493.3 Da
Half-life ~2 hoursShort (hours)
Route(s) SubcutaneousSubcutaneous, Topical, Intranasal
Mechanism & Research
Primary mechanism Thymosin Alpha-1 stimulates T-cell differentiation and maturation, particularly enhancing T-helper cell (Th1) responses. This drives improved cell-mediated immunity — the arm of the immune system responsible for clearing… LL-37 disrupts microbial membranes through electrostatic interaction — its cationic amphipathic helical structure inserts into negatively charged bacterial membranes, causing lethal membrane permeabilisation. This mechan…
Research status Research Compound Research Compound
Evidence summary Thymosin Alpha-1 has extensive human clinical data from its regulatory approval in Asia and Europe for viral hepatitis and cancer adjunct therapy. Longevity applications build on this established safety and immune-modula… LL-37 has been studied extensively for wound healing, respiratory infections (including COVID-19 lung immunity), and more recently for senolytic applications. Its broad antimicrobial and immunomodulatory profile makes it…
Protocol & Dosing
Typical dose 1.6 mg per injection (standard clinical dose)1–5 mg per injection or topical application
Frequency 2x per week for 6–12 weeksDaily
Duration 6–12 weeks4–8 weeks
Timing Any time of dayAny time
Safety
Common side effects
  • Injection site redness
  • Mild flu-like symptoms (first injection)
  • Fatigue (transient)
  • Injection site pain (cytokine release)
  • Mild erythema
  • Headache (rare)
Contraindications
  • Active autoimmune disease (immune stimulation risk)
  • Post-organ transplant (immunosuppression may be reversed)
  • Known allergy to thymic peptides
  • Autoimmune conditions (immune stimulation)
  • Active lupus (LL-37 is a lupus autoantigen in some patients)
  • Pregnancy (no data)
Anti-doping Not Prohibited Not Prohibited
Deeper reading
Related peptides Epithalon, TB-500, LL-37 BPC-157, GHK-Cu, KPV
Full profile Read full Thymosin Alpha-1 profile → Read full LL-37 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.